Vertex Pharmaceuticals Incorporated (VRTX) Business Profile

What it does

Vertex Pharmaceuticals is a biotechnology company that develops and sells medicines for serious diseases, focusing on specialty markets. Headquartered in Boston, it is led by chief executive Reshma Kewalramani.

Its largest business treats cystic fibrosis (CF), an inherited disease that can cause lung infections and progressive lung damage. Vertex’s CF medicines improve the function of a defective protein involved in the disease. They include TRIKAFTA, sold as KAFTRIO in some markets, and the once-daily medicine ALYFTREK.

Vertex also sells CASGEVY, a gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, two inherited blood disorders. Patients’ cells are collected, edited at a manufacturing facility and returned for infusion at an authorized treatment center. JOURNAVX is an oral, non-opioid medicine approved in the United States for moderate-to-severe acute pain in adults.

Following the acquisition of Crinetics, Vertex added Palsonify for acromegaly to its commercial medicines. It sells primarily to specialty pharmacies and distributors, as well as wholesalers, hospitals, clinics and treatment centers. Its research pipeline includes potential treatments for kidney diseases, chronic pain and type 1 diabetes.

How it makes money

Vertex earns revenue principally by selling prescription medicines. Its pharmaceuticals segment recorded $12.0 billion in FY2025 revenue.

TRIKAFTA/KAFTRIO generated $10.3 billion in FY2025, or 84.7% of revenue. ALYFTREK generated $837.8 million in the same year. Both are CF medicines, and Vertex expects the majority of people with CF to transition to ALYFTREK over time. Its CF medicines treat an ongoing genetic disease rather than being administered as a one-time procedure.

Outside CF, CASGEVY generated $115.8 million in FY2025, while JOURNAVX generated $59.6 million. CASGEVY is intended as a potential one-time functional cure: revenue depends on patients progressing through collection, manufacturing and infusion. JOURNAVX treats acute pain, which typically resolves in days or weeks. Palsonify added another commercial medicine after the Crinetics acquisition.

The amounts Vertex receives depend partly on negotiations and reimbursement arrangements with government agencies, insurers and other payors. In the United States, participation in government pricing programs involves rebates or discounts. Outside the United States, some countries require reimbursement negotiations before commercial supply can begin, and those discussions often result in prices below the net price obtainable in the United States.

Vertex’s commercial work includes securing coverage and formulary placement, promoting approved uses to healthcare professionals, and helping eligible patients understand coverage or obtain assistance.

Customers and how it sells

Vertex sells globally through a limited number of specialty pharmacies and specialty distributors, as well as certain major U.S. wholesalers. In the United States, those customers resell its medicines to patients, healthcare providers, retail pharmacies, hospitals and authorized treatment centers.

Outside the United States, sales flow mainly through distributors and retail pharmacies, as well as hospitals and clinics, many of which are government-owned or supported. In some markets Vertex may sell CASGEVY directly to authorized treatment centers. It also contracts with government agencies to make its medicines eligible for purchase or reimbursement.

The United States accounted for $7.5 billion, or 62.9%, of FY2025 revenue. Europe accounted for $3.5 billion, or 28.8%, and other geographies contributed $992.4 million. Vertex’s CF medicines are reimbursed or accessible across multiple continents.

CASGEVY is broadly reimbursed by U.S. third-party payors, including government and commercial payors. Outside the United States, Vertex has secured access in several European and Middle Eastern countries. For JOURNAVX, Vertex had secured access with the national pharmacy benefit managers and coverage across commercial and government payors as of January 2026.

Suppliers and costs

Vertex uses its own capabilities and a global network of third parties to manufacture and distribute commercial medicines and clinical trial products. It also builds supply chains for newly approved products and adapts existing ones for new formulations or greater production scale.

Manufacturing processes for biological, cell and gene therapies can require different systems, equipment, facilities and expertise from those used for small-molecule medicines. For CASGEVY, patient cells must be collected, sent to a facility for editing and returned to a treatment center. Manufacturing CASGEVY costs significantly more as a percentage of revenue than manufacturing its CF medicines.

Manufacturers and suppliers must meet detailed quality requirements and are subject to regulatory inspections. Key materials suppliers must be named in product applications, and qualifying a replacement can cause delays. Vertex also invests in research and development, sales and other commercial activities.

The company raised $4.5 billion of term loans to fund part of the Crinetics acquisition.

Competitive position

Vertex competes with branded and generic medicines already on the market, as well as products and technologies under development. Competition can turn on safety, effectiveness, convenience, dosing, price, insurance coverage, regulatory exclusivity and patents. The speed of development, approval and supply can also affect whether a medicine gains acceptance.

No specific competing company is named. Academic institutions, government agencies and other research organizations also work on therapies in areas Vertex targets.

In CF, Vertex’s medicines are used by people in the United States, Europe, Australia and Canada. ALYFTREK is taken once daily, and Vertex continues to develop next-generation CF treatments. Our reading: the established CF patient base and Vertex’s successive medicines give it a meaningful competitive position, although new treatments and pricing pressure can challenge it.

Vertex works to secure reimbursement and formulary access for its medicines, and CASGEVY requires authorized centers and specialized manufacturing. Our reading: coverage relationships and treatment infrastructure can support access, but they do not guarantee preference over other therapies. Our reading: Vertex’s pipeline and research capabilities may help it compete in additional diseases, but their value depends on clinical results, approvals and commercial acceptance.

Growth opportunities

Vertex seeks to increase the number of people receiving its CF medicines through approvals for younger patients, reimbursement agreements and expansion into additional geographies. The company has initiated global submissions for ALYFTREK in younger children.

Outside CF, Vertex is expanding access to CASGEVY and JOURNAVX. CASGEVY recently received approval for younger patients in the United States, UAE, Bahrain and the United Kingdom. Following its Crinetics acquisition, Vertex is launching Palsonify for acromegaly in the United States.

The company is developing povetacicept for kidney and other immune-mediated diseases. Its application for accelerated approval in IgA nephropathy is under FDA priority review. Vertex has completed enrollment in the pivotal trial of inaxaplin for APOL1-mediated kidney disease and expects interim results early in 2027.

In type 1 diabetes, Vertex has prioritized VX017, a cell therapy designed for people with all blood types, and has begun dosing patients in a clinical study. The company estimates that approximately 120,000 people could be eligible. It is also studying suzetrigine for diabetic peripheral neuropathy and expects results from both studies by mid-2027.

Structural risks

• CF concentration: Substantially all net product revenue has come from CF medicines. Competition, supply disruptions, safety issues or inadequate reimbursement could affect Vertex’s ability to sustain those sales and fund operations.
• Drug development: Product candidates can fail to establish safety or effectiveness, obtain approval, be manufactured economically or gain market acceptance. Developing additional medicines requires significant resources and has uncertain outcomes.
• Pricing and reimbursement: Sales depend heavily on government and private payors. Price controls, discounts, restrictive coverage decisions or lengthy reimbursement negotiations can limit revenue and delay access.
• CASGEVY delivery: Cell collection, manufacturing and administration are complex and resource-intensive. Acceptance also depends partly on side effects associated with the procedure, including the conditioning treatment before infusion.
• Commercial competition: JOURNAVX may face lower-cost alternatives and challenges in gaining acceptance among physicians, patients and payors. New products or technologies can also slow sales growth or reduce sales of Vertex medicines.
• Manufacturing and regulation: Suppliers and facilities must comply with quality rules and pass inspections. Qualifying a new supplier can delay production, while safety findings or regulatory noncompliance can delay, limit or prevent approval.

Bottom line

Our reading

Our reading: Vertex is a biotechnology business whose sales still rest heavily on established CF medicines, even as it builds businesses in gene therapy, pain and rare endocrine disease. Its existing patient base and access arrangements support that business, but revenue concentration, reimbursement pressure and complex manufacturing remain important exposures. Its pipeline offers routes into additional diseases, with their commercial contribution dependent on trial results, approval and patient access.